Picanco-Castro Virgínia, Biaggio Rafael Tage, Cova Dimas Tadeu, Swiech Kamilla
Faculty of Pharmaceutical Sciences of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto-SP, Brazil.
Protein Pept Lett. 2013 Dec;20(12):1373-81. doi: 10.2174/092986652012131112130322.
Over the past 20 years the demand for recombinant proteins has increased significantly. Mammalian cell lines have been extensively used to produce recombinant proteins. This expression system offers several advantages over microbial systems, mammalian cells have the cellular machinery to promote the secretion of the recombinant product and the posttranslational modifications, like glycosylation that is present in many of recombinant therapeutic proteins in the market. Human cell lines have emerged as a new and powerful alternative for production of such products. These cells are able to produce recombinant proteins with posttranslational modifications more similar to their natural counterparts, producing proteins with human-like glycosylation pattern avoiding immunogenic reactions against epitopes nonhumans. This review presents the available human cell lines that can be used in pharmaceutical industry, the advantages of this expression system and the main efforts made in this field.
在过去20年里，对重组蛋白的需求显著增加。哺乳动物细胞系已被广泛用于生产重组蛋白。与微生物系统相比，这种表达系统具有几个优势，哺乳动物细胞拥有促进重组产物分泌和进行翻译后修饰的细胞机制，比如市场上许多重组治疗性蛋白中存在的糖基化修饰。人源细胞系已成为生产此类产品的一种新的强大替代方案。这些细胞能够产生具有更类似于其天然对应物的翻译后修饰的重组蛋白，产生具有类人糖基化模式的蛋白，避免针对非人类表位的免疫反应。本综述介绍了可用于制药行业的现有人类细胞系、该表达系统的优势以及该领域所做的主要工作。
